MyBiotics Pharma
Clinically Effective Microbiome and Probiotic Products
Company Overview
Snapshot
Founded in July 2014 by Didi Daboush, MyBiotics Pharma operates with 11–50 employees. The company has raised $11.27 million across 5 funding rounds and has 1 investor. In January 2022, MyBiotics Pharma successfully completed a Phase I clinical trial for its MBX-SD-202 whole microbiome treatment.
Business overview
MyBiotics Pharma is a microbiome company dedicated to enhancing human health through advanced probiotic solutions. The company has developed a novel technological platform for creating microbiome-related drugs and supplements, utilizing innovative formulation, delivery, and culturing methods to improve viability, resistance, and colonization. Its core technologies include MyCrobe, SuperDonor, and Super Donor Select, supported by the MyLiveIn computational and AI platform. MyBiotics Pharma serves the health tech and life sciences sectors, with products in clinical stages targeting medical indications such as C. diff, oncology, dermatology, and women's health.
Strategic signal
In January 2022, MyBiotics Pharma announced the successful completion of a Phase I clinical trial for its MBX-SD-202 whole microbiome treatment. This milestone is significant as it validates the safety of their SuperDonor™ technology in healthy volunteers, paving the way for further clinical development in recurrent C. diff infection and other indications like oncology. For investors, this signals strong progress in their clinical pipeline and de-risks future development, demonstrating the potential for their proprietary microbiome restoration therapies.
Log in to access full profile ›Company Intelligence Q&A
- What was the outcome of the Phase I clinical trial for MBX-SD-202?
- In January 2022, MyBiotics Pharma successfully completed the Phase I clinical trial for its MBX-SD-202 whole microbiome treatment. The trial confirmed the safety of MBX-SD-202 in healthy volunteers, supporting further development of the company's SuperDonor™ technology for recurrent Clostridioides difficile infection and other medical indications.
- What strategic partnership did MyBiotics Pharma form in April 2021?
- In April 2021, MyBiotics Pharma partnered with Hadasit Medical Research Services and Development Ltd., the technology transfer arm of Hadassah Medical Center. This collaboration aims to develop microbiome-based therapies to enhance cancer immunotherapies for melanoma patients.
- Which companies did MyBiotics Pharma collaborate with for reproductive medicine and maternal health?
- In February 2021, MyBiotics Pharma collaborated with Ferring Pharmaceuticals and Rebiotix Inc. to develop live microbiota-based biotherapeutics for bacterial vaginosis, aiming to reduce antibiotic reliance and provide long-term treatment solutions in women's health.
- Which investor participated in MyBiotics Pharma's February 2021 funding round?
- In February 2021, MyBiotics Pharma received an investment from Mii Fund, a partnership with Maruho Co. Ltd., to advance its microbiome therapeutics pipeline and enhance its platform technologies, including a new development program in skin microbiome.
- What was the nature of the collaboration between Galmed and MyBiotics Pharma in November 2020?
- In November 2020, Galmed Pharmaceuticals and MyBiotics Pharma entered a research and development collaboration. The partnership focuses on identifying and optimizing the microbiome repertoire associated with the response to Aramchol, aiming to develop a standalone microbiome-based treatment for non-alcoholic steatohepatitis (NASH) and fibrosis.